Tucidinostat

Generic Name
Tucidinostat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H19FN4O2
CAS Number
1616493-44-7
Unique Ingredient Identifier
87CIC980Y0
Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)

Not Applicable
Conditions
Peripheral T Cell Lymphoma
Interventions
Drug: Chidamide
First Posted Date
2017-08-31
Last Posted Date
2017-08-31
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
39
Registration Number
NCT03268889
Locations
🇨🇳

the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

First Posted Date
2017-08-10
Last Posted Date
2021-03-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
100
Registration Number
NCT03245905
Locations
🇨🇳

Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

First Posted Date
2017-05-12
Last Posted Date
2018-07-18
Lead Sponsor
Sichuan University
Target Recruit Count
93
Registration Number
NCT03151876
Locations
🇨🇳

Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China

🇨🇳

General Hospital of Lanzhou military command, Lanzhou, Gansu, China

🇨🇳

Peking university third hospital, Beijing, Beijing, China

and more 15 locations

Efficacy and Safety of Chidamide in CBF Leukemia

Phase 1
Conditions
AML
Interventions
Drug: Cytarabine
Drug: Chidamide
First Posted Date
2017-01-25
Last Posted Date
2019-03-22
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
250
Registration Number
NCT03031262
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

First Posted Date
2017-01-18
Last Posted Date
2017-01-18
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
174
Registration Number
NCT03023358
Locations
🇨🇳

Ru Feng, Guangzhou, Guangdong, China

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

First Posted Date
2016-12-08
Last Posted Date
2016-12-08
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
100
Registration Number
NCT02987244
Locations
🇨🇳

Peking Union medical college hospital, Beijing, Beijing, China

🇨🇳

Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Phase 2
Conditions
Peripheral T Cell Lymphoma
Interventions
Drug: Chidamide
First Posted Date
2016-10-26
Last Posted Date
2016-10-26
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
12
Registration Number
NCT02944812
Locations
🇨🇳

Guangdong general hospital, Guangzhou, Guangdong, China

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Phase 2
Conditions
Adenocystic Carcinoma
Interventions
Drug: Chidamide
First Posted Date
2016-08-30
Last Posted Date
2017-08-31
Lead Sponsor
Dong mei
Target Recruit Count
30
Registration Number
NCT02883374
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

First Posted Date
2016-06-22
Last Posted Date
2019-07-24
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
30
Registration Number
NCT02809573
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Phase 2
Conditions
Peripheral T Cell Lymphoma
Interventions
Drug: Chidamide
First Posted Date
2016-04-28
Last Posted Date
2017-11-14
Lead Sponsor
Ruijin Hospital
Target Recruit Count
33
Registration Number
NCT02753543
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy